Home › Companies › Heron Therapeutics, Inc. › 2025-2026

Heron Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Heron Therapeutics, Inc.’s Form 8-K, filed 2026-06-16 (Item 5.07 on EDGAR). Page generated 04 October 2026.

14Ballot items
141Asset managers
1,778Fund votes
2026-06-11Main meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Heron Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Heron Therapeutics, Inc.

These tallies are Heron Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-16 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. Heron Therapeutics, Inc. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

Heron Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-11 (Form 8-K, filed 2026-06-16)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Mr. Collard	87,289,779	4,336,869	185,208	--	50,116,083	Majority: yes
Elect Director: Mr. Cusack	88,537,725	3,088,305	185,826	--	50,116,083	Majority: yes
Elect Director: Dr. Dissanaike	87,960,023	3,729,614	122,219	--	50,116,083	Majority: yes
Elect Director: Mr. Johnson	87,703,801	3,972,919	135,136	--	50,116,083	Majority: yes
Elect Director: Mr. Kaseta	88,236,408	3,424,597	150,851	--	50,116,083	Majority: yes
Elect Director: Mr. Morgan	88,295,437	3,381,282	135,137	--	50,116,083	Majority: yes
Elect Director: Mr. Waage	85,276,872	6,399,195	135,789	--	50,116,083	Majority: yes
Proposal 2: The Company's stockholders ratified the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:	139,715,514	1,706,193	506,232	--	0	Majority: yes
Proposal 3: The Company's stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025:	77,315,474	12,117,861	2,378,521	--	50,116,083	Majority: yes
Proposal 4: The Company's stockholders approved the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an addit	75,620,741	13,846,030	2,345,085	--	50,116,083	Majority: yes
Proposal 5: The Company's stockholders approved the amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares:	83,765,950	6,496,205	1,549,701	--	50,116,083	Majority: yes
Proposal 6: The Company's stockholders ratified, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan:	88,182,895	3,442,815	186,146	--	50,116,083	Majority: yes

Source: Heron Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-16 — read the filing on EDGAR.

Heron Therapeutics, Inc. — official shareholder meeting results, meeting held 2025-10-13 (Form 8-K, filed 2025-10-15)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 1: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at the option of the holder, of convertible senior unsecured promissor	89,632,206	5,575,457	218,161	--	0	Majority: yes
Proposal 2: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by	91,534,602	3,672,091	219,131	--	0	Majority: yes

Source: Heron Therapeutics, Inc., Form 8-K, filed with the SEC on 2025-10-15 — read the filing on EDGAR.

How asset managers voted at the Heron Therapeutics, Inc. 2025-2026 meetings

Each item below shows how the 141 asset managers that disclosed a Heron Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCAL YEAR ENDED DECEMBER 31, 2025.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 7 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%14%

FOR: 77,315,474AGAINST: 12,117,861

Heron Therapeutics, Inc.’s own tally for this item (“Proposal 3: The Company's stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025:”): 77,315,474 for, 12,117,861 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 41% for, 6% against (47.2% of the company cast a for/against vote).

The 137 asset managers below cast 89% of the shares they voted on this item FOR (70,164,088 for, 8,295,260 against).

FOR 89%11%

FOR: 70,164,088 (89.4%)AGAINST: 8,295,260 (10.6%)ABSTAIN: 16 (0.0%)

Largest asset managers voting on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCA” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Rubric Capital Management LP	26,713,503	0	0	For
Clearline Capital LP	11,586,116	0	0	For
Velan Capital Investment Management LP	10,519,836	0	0	For
ORBIMED ADVISORS LLC	0	6,127,998	0	Against
Vanguard	6,014,117	5,570	16	For
Charles Schwab	2,757,548	0	0	For
PALISADE CAPITAL MANAGEMENT, LP	2,391,618	0	0	For
BlackRock	1,938,647	4,424	0	For
State Street	1,879,650	11,064	0	For
Stonepine Capital Management, LLC	1,402,191	0	0	For
Goldman Sachs	688,532	0	0	For
Northern Trust	605,710	4,681	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Orchard Capital Management, LLC	0	458,766	0	Against
AQR	414,902	0	0	For
MELLON INVESTMENTS Corp	377,347	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	358,920	0	0	For
SEI	0	329,907	0	Against
Fidelity	257,892	0	0	For
Renaissance	251,892	0	0	For
DE Shaw	246,404	0	0	For
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	0	243,570	0	Against
NexPoint Advisors, L.P.	0	242,950	0	Against
HIGHLAND GLOBAL ALLOCATION FUND	0	232,800	0	Against
AllianceBernstein	198,550	0	0	For

Showing the 25 largest of 137 asset managers. See all 137 in the interactive database.

2. TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THE CONVERSION OF CONVERTIBLE SENIOR UNSECURED PROMISSORY NOTES DUE 2031 HELD BY SEVERAL NON-AFFILIATED PURCHASERS, WHICH COULD, UNDER CERTAIN CIRCUMSTANCES THAT MAY OCCUR IN THE FUTURE, EXCEED 19.99% OF THE NUMBER OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING

CAPITAL STRUCTUREMajority of the votes cast: yes

Meeting held 2025-10-13.

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 89,632,206AGAINST: 5,575,457

Heron Therapeutics, Inc.’s own tally for this item (“Proposal 1: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at the option of the holder, o”): 89,632,206 for, 5,575,457 against, per its Form 8-K filed 2025-10-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 47.4% for, 3% against (50.3% of the company cast a for/against vote).

The 38 asset managers below cast 99% of the shares they voted on this item FOR (11,738,277 for, 134,717 against).

FOR 99%

FOR: 11,738,277 (98.9%)AGAINST: 134,717 (1.1%)

Largest asset managers voting on “TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMO” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,134,000	0	For
BlackRock	1,933,129	0	For
T. Rowe Price	1,324,908	0	For
Charles Schwab	759,955	0	For
State Street	652,774	7,846	For
TIAA	323,440	0	For
Goldman Sachs	275,907	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
SEI	141,815	0	For
Lincoln Financial	0	118,392	Against
QUANTITATIVE MASTER SERIES LLC	103,657	0	For
Fidelity	90,597	0	For
AIG/SunAmerica	79,593	0	For
Equitable	79,023	0	For
John Hancock	78,683	0	For
Global X	75,637	0	For
Bridge Builder Trust	69,478	0	For
Pacific Life	67,920	0	For
PACE SELECT ADVISORS TRUST	62,600	0	For
Brighthouse	56,019	0	For
Voya	36,633	0	For
ProShares	34,403	0	For
Jacob Funds Inc.	32,941	0	For
MASTER INVESTMENT PORTFOLIO	22,992	0	For
Calvert	15,618	0	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

3. TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THE CONVERSION OF THE COMPANY'S SERIES A CONVERTIBLE PREFERRED STOCK HELD BY SEVERAL NON-AFFILIATED HOLDERS, WHICH COULD, UNDER CERTAIN CIRCUMSTANCES THAT MAY OCCUR IN THE FUTURE, EXCEED 19.99% OF THE NUMBER OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING PRIOR

CAPITAL STRUCTUREMajority of the votes cast: yes

Meeting held 2025-10-13.

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 91,534,602AGAINST: 3,672,091

Heron Therapeutics, Inc.’s own tally for this item (“Proposal 2: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Seri”): 91,534,602 for, 3,672,091 against, per its Form 8-K filed 2025-10-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 48.4% for, 2% against (50.3% of the company cast a for/against vote).

The 38 asset managers below cast 100% of the shares they voted on this item FOR (11,872,994 for, 0 against).

FOR 100%

FOR: 11,872,994 (100.0%)

Largest asset managers voting on “TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMO” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
Vanguard	5,134,000	For
BlackRock	1,933,129	For
T. Rowe Price	1,324,908	For
Charles Schwab	759,955	For
State Street	660,620	For
TIAA	323,440	For
Goldman Sachs	275,907	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	For
SEI	141,815	For
Lincoln Financial	118,392	For
QUANTITATIVE MASTER SERIES LLC	103,657	For
Fidelity	90,597	For
AIG/SunAmerica	79,593	For
Equitable	79,023	For
John Hancock	78,683	For
Global X	75,637	For
Bridge Builder Trust	69,478	For
Pacific Life	67,920	For
PACE SELECT ADVISORS TRUST	62,600	For
Brighthouse	56,019	For
Voya	36,633	For
ProShares	34,403	For
Jacob Funds Inc.	32,941	For
MASTER INVESTMENT PORTFOLIO	22,992	For
Calvert	15,618	For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

4. To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Adam Morgan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 88,295,437AGAINST: 3,381,282

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Morgan”): 88,295,437 for, 3,381,282 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 46.6% for, 2% against (48.4% of the company cast a for/against vote).

The 36 asset managers below cast 98% of the shares they voted on this item FOR (10,026,037 for, 238,090 against).

FOR 98%

FOR: 10,026,037 (97.7%)AGAINST: 238,090 (2.3%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,843,515	5,512	1	For
Charles Schwab	1,378,500	0	0	For
State Street	599,122	0	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	118,392	0	0	For
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	0	15,618	0	Against
T. Rowe Price	13,942	0	0	For
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	4,679	0	0	For
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

5. To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Christian Waage

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 85,276,872AGAINST: 6,399,195

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Waage”): 85,276,872 for, 6,399,195 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 45.1% for, 3% against (48.4% of the company cast a for/against vote).

The 36 asset managers below cast 82% of the shares they voted on this item FOR (8,380,271 for, 1,883,855 against).

FOR 82%AGAINST 18%

FOR: 8,380,271 (81.6%)AGAINST: 1,883,855 (18.4%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,832,187	16,839	1	For
Charles Schwab	0	1,378,500	0	Against
State Street	599,122	0	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	0	164,898	0	Against
BlackRock	143,606	0	0	For
Lincoln Financial	118,392	0	0	For
Global X	0	73,839	0	Against
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	0	15,618	0	Against
T. Rowe Price	13,942	0	0	For
Venerable Variable Insurance Trust	0	12,671	0	Against
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	4,679	0	0	For
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

6. To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Collard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 87,289,779AGAINST: 4,336,869

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Collard”): 87,289,779 for, 4,336,869 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 46.1% for, 2% against (48.4% of the company cast a for/against vote).

The 36 asset managers below cast 98% of the shares they voted on this item FOR (10,047,141 for, 216,984 against).

FOR 98%

FOR: 10,047,141 (97.9%)AGAINST: 216,984 (2.1%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,849,001	24	1	For
Charles Schwab	1,378,500	0	0	For
State Street	599,122	0	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	118,392	0	0	For
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	15,618	0	0	For
T. Rowe Price	13,942	0	0	For
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	4,679	0	0	For
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

7. To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Johnson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 87,703,801AGAINST: 3,972,919

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Johnson”): 87,703,801 for, 3,972,919 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 46.3% for, 2% against (48.4% of the company cast a for/against vote).

The 36 asset managers below cast 98% of the shares they voted on this item FOR (10,029,402 for, 234,724 against).

FOR 98%

FOR: 10,029,402 (97.7%)AGAINST: 234,724 (2.3%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,832,199	16,827	1	For
Charles Schwab	1,378,500	0	0	For
State Street	599,122	0	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	118,392	0	0	For
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	15,618	0	0	For
T. Rowe Price	13,942	0	0	For
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	4,679	0	0	For
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

8. To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Michael Kaseta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 88,236,408AGAINST: 3,424,597

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Kaseta”): 88,236,408 for, 3,424,597 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 46.6% for, 2% against (48.4% of the company cast a for/against vote).

The 36 asset managers below cast 98% of the shares they voted on this item FOR (10,047,148 for, 216,978 against).

FOR 98%

FOR: 10,047,148 (97.9%)AGAINST: 216,978 (2.1%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,849,008	18	1	For
Charles Schwab	1,378,500	0	0	For
State Street	599,122	0	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	118,392	0	0	For
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	15,618	0	0	For
T. Rowe Price	13,942	0	0	For
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	4,679	0	0	For
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

9. To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Sharmila Dissanaike, M.D., FACS, FCCM

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 87,960,023AGAINST: 3,729,614

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Dissanaike”): 87,960,023 for, 3,729,614 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 46.5% for, 2% against (48.4% of the company cast a for/against vote).

The 36 asset managers below cast 99.6% of the shares they voted on this item FOR (10,232,767 for, 31,360 against).

FOR 99.6%

FOR: 10,232,767 (99.7%)AGAINST: 31,360 (0.3%)

Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,837,694	11,333	For
Charles Schwab	1,378,500	0	For
State Street	599,122	0	For
Jacob Funds Inc.	521,446	0	For
Goldman Sachs	473,272	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	For
Fidelity	197,639	0	For
Equitable	196,283	0	For
SEI	164,898	0	For
BlackRock	143,606	0	For
Lincoln Financial	118,392	0	For
Global X	73,839	0	For
Bridge Builder Trust	68,575	0	For
Pacific Life	57,569	0	For
Invesco	44,140	0	For
Victory Capital	21,233	0	For
ProShares	19,299	0	For
AIG/SunAmerica	17,391	0	For
Calvert	0	15,618	Against
T. Rowe Price	13,942	0	For
Venerable Variable Insurance Trust	12,671	0	For
Principal	6,978	0	For
Brinker Capital Destinations Trust	4,679	0	For
Nationwide	4,470	0	For
Morgan Stanley	4,190	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

10. To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Tom Cusack

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 88,537,725AGAINST: 3,088,305

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Cusack”): 88,537,725 for, 3,088,305 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 46.8% for, 2% against (48.4% of the company cast a for/against vote).

The 36 asset managers below cast 98% of the shares they voted on this item FOR (10,047,148 for, 216,978 against).

FOR 98%

FOR: 10,047,148 (97.9%)AGAINST: 216,978 (2.1%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,849,008	18	1	For
Charles Schwab	1,378,500	0	0	For
State Street	599,122	0	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	118,392	0	0	For
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	15,618	0	0	For
T. Rowe Price	13,942	0	0	For
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	4,679	0	0	For
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

11. TO AMEND THE COMPANY'S 1997 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY AN ADDITIONAL 10,000,000 SHARES.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 2 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 83,765,950AGAINST: 6,496,205

Heron Therapeutics, Inc.’s own tally for this item (“Proposal 5: The Company's stockholders approved the amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an addi”): 83,765,950 for, 6,496,205 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 44% for, 3% against (47.7% of the company cast a for/against vote).

The 36 asset managers below cast 98% of the shares they voted on this item FOR (10,047,117 for, 217,000 against).

FOR 98%

FOR: 10,047,117 (97.9%)AGAINST: 217,000 (2.1%)ABSTAIN: 10 (0.0%)

Largest asset managers voting on “TO AMEND THE COMPANY'S 1997 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMM” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,848,977	40	10	For
Charles Schwab	1,378,500	0	0	For
State Street	599,122	0	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	118,392	0	0	For
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	15,618	0	0	For
T. Rowe Price	13,942	0	0	For
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	4,679	0	0	For
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

12. TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2007 AMENDED AND RESTATED EQUITY INCENTIVE PLAN, TO, AMONG OTHER THINGS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY AN ADDITIONAL 16,560,000 SHARES.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%AGAINST 15%

FOR: 75,620,741AGAINST: 13,846,030

Heron Therapeutics, Inc.’s own tally for this item (“Proposal 4: The Company's stockholders approved the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock author”): 75,620,741 for, 13,846,030 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 40% for, 7% against (47.3% of the company cast a for/against vote).

The 36 asset managers below cast 88% of the shares they voted on this item FOR (9,029,248 for, 1,234,863 against).

FOR 88%12%

FOR: 9,029,248 (88.0%)AGAINST: 1,234,863 (12.0%)ABSTAIN: 16 (0.0%)

Largest asset managers voting on “TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2007 AMENDED AND RESTATED EQUITY INCENTIVE PLAN, TO,” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,837,633	11,378	16	For
Charles Schwab	1,378,500	0	0	For
State Street	0	599,122	0	Against
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,638	1	0	For
Equitable	75,213	121,070	0	Against
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	0	118,392	0	Against
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	0	44,140	0	Against
Victory Capital	0	21,233	0	Against
ProShares	0	19,299	0	Against
AIG/SunAmerica	0	17,391	0	Against
Calvert	0	15,618	0	Against
T. Rowe Price	0	13,942	0	Against
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	0	6,978	0	Against
Brinker Capital Destinations Trust	0	4,679	0	Against
Nationwide	4,470	0	0	For
Morgan Stanley	0	4,190	0	Against

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

13. TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-06-11.

99% Majority: yes · of votes cast

FOR 99%

FOR: 139,715,514AGAINST: 1,706,193

Heron Therapeutics, Inc.’s own tally for this item (“Proposal 2: The Company's stockholders ratified the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:”): 139,715,514 for, 1,706,193 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 74% for, 1.0% against (75% of the company cast a for/against vote).

The 36 asset managers below cast 99.9% of the shares they voted on this item FOR (10,258,627 for, 5,500 against).

FOR 99.9%

FOR: 10,258,627 (99.9%)AGAINST: 5,500 (0.1%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR E” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,843,527	5,500	1	For
Charles Schwab	1,378,500	0	0	For
State Street	599,122	0	0	For
Jacob Funds Inc.	521,446	0	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	118,392	0	0	For
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	15,618	0	0	For
T. Rowe Price	13,942	0	0	For
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	4,679	0	0	For
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

14. TO RATIFY, ON A NONBINDING ADVISORY BASIS, THE ADOPTION OF THE TAX BENEFITS PRESERVATION PLAN.

OTHERMajority of the votes cast: yes

Meeting held 2026-06-11.

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 88,182,895AGAINST: 3,442,815

Heron Therapeutics, Inc.’s own tally for this item (“Proposal 6: The Company's stockholders ratified, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan:”): 88,182,895 for, 3,442,815 against, per its Form 8-K filed 2026-06-16 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 189,279,369 outstanding shares: 46.6% for, 2% against (48.4% of the company cast a for/against vote).

The 36 asset managers below cast 96% of the shares they voted on this item FOR (9,900,066 for, 364,060 against).

FOR 96%

FOR: 9,900,066 (96.5%)AGAINST: 364,060 (3.5%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “TO RATIFY, ON A NONBINDING ADVISORY BASIS, THE ADOPTION OF THE TAX BENEFITS PRESERVATION PLAN.” at Heron Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,849,007	19	1	For
Charles Schwab	1,378,500	0	0	For
State Street	592,854	6,268	0	For
Jacob Funds Inc.	304,486	216,960	0	For
Goldman Sachs	473,272	0	0	For
HIGHLAND GLOBAL ALLOCATION FUND	232,800	0	0	For
Fidelity	197,639	0	0	For
Equitable	196,283	0	0	For
SEI	164,898	0	0	For
BlackRock	143,606	0	0	For
Lincoln Financial	0	118,392	0	Against
Global X	73,839	0	0	For
Bridge Builder Trust	68,575	0	0	For
Pacific Life	57,569	0	0	For
Invesco	44,140	0	0	For
Victory Capital	21,233	0	0	For
ProShares	19,299	0	0	For
AIG/SunAmerica	17,391	0	0	For
Calvert	15,618	0	0	For
T. Rowe Price	0	13,942	0	Against
Venerable Variable Insurance Trust	12,671	0	0	For
Principal	6,978	0	0	For
Brinker Capital Destinations Trust	0	4,679	0	Against
Nationwide	4,470	0	0	For
Morgan Stanley	4,190	0	0	For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Largest Heron Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Heron Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 189,279,369 shares outstanding at the time of that meeting.

Top Heron Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Rubric Capital Management LP	14.11%
2	Clearline Capital LP	6.12%
3	Velan Capital Investment Management LP	5.56%
4	ORBIMED ADVISORS LLC	3.24%
5	Vanguard	3.18%
6	Charles Schwab	1.46%
7	PALISADE CAPITAL MANAGEMENT, LP	1.26%
8	BlackRock	1.03%
9	State Street	1.00%
10	Stonepine Capital Management, LLC	0.74%

Reported Heron Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Heron Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Rubric Capital Management LP	15.87%	DEF14A
Clearline Capital, L.P.	6.46%	DEF14A
Current Executive Officers and Directors as a group (10 persons)	6.12%	DEF14A
BlackRock	5.34%	13F
Subsidiaries or business divisions of Vanguard Group Inc.	5.19%	DEF14A
Vanguard Group	5.19%	13F
Adam Morgan	4.99%	DEF14A
Millennium Management	4.03%	13F
Geode Capital	2.12%	13F
State Street	2.03%	13F

Percentages above are of 189,279,369 shares outstanding, as reported by Heron Therapeutics, Inc. on its Form 10-Q dated 2026-05-06 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Heron Therapeutics, Inc.’s 10-Q dated 2026-05-06. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Heron Therapeutics, Inc.'s 2 shareholder meetings in the 2025-2026 proxy season (held 2025-10-13 and 2026-06-11), 141 asset managers reported how they voted on 14 ballot items in their SEC Form N-PX filings, covering 1,778 separate fund positions. On the most widely held item of the season, voted at the meeting held 2026-06-11 — TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS… — FOR was 86% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Heron Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-16.

Heron Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).